NASDAQ:QURE uniQure (QURE) Stock Price, News & Analysis $22.59 +0.05 (+0.22%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$22.54 -0.05 (-0.22%) As of 10/9/2026 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About uniQure Stock (NASDAQ:QURE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get uniQure alerts:Sign Up Key Stats Today's Range$22.23▼$23.0050-Day Range$22.54▼$51.0552-Week Range$8.73▼$71.50Volume2.05 million shsAverage Volume3.49 million shsMarket Capitalization$1.57 billionP/E RatioN/ADividend YieldN/APrice Target$53.73Consensus RatingModerate Buy Company Overview uniQure N.V. is a biotechnology company focused on developing gene therapies intended to treat serious and potentially life-threatening diseases. The company uses adeno-associated virus (AAV) delivery technology to introduce genetic material into patients’ cells, with the goal of addressing the underlying causes of disease through a single administration. uniQure’s lead commercial product, Hemgenix (etranacogene dezaparvovec), is a gene therapy for adults with hemophilia B who use factor IX replacement therapy. Hemgenix was developed by uniQure and is commercialized by CSL under a licensing and collaboration agreement. The company’s investigational pipeline has included gene therapies for Huntington’s disease, epilepsy and other severe conditions. Founded in 1998 as Amsterdam Molecular Therapeutics, uniQure is headquartered in Lexington, Massachusetts, and maintains operations in the Netherlands. Its research, clinical development and commercial activities serve patients and healthcare markets in the United States, Europe and other international regions through internal programs and strategic partnerships.AI Generated. May Contain Errors. Read More uniQure Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks74th Percentile Overall ScoreQURE MarketRank™: uniQure scored higher than 74% of companies evaluated by MarketBeat, and ranked 177th out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatinguniQure has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 11 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialuniQure has a consensus price target of $53.73, representing about 137.8% upside from its current price of $22.59.Amount of Analyst CoverageuniQure has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about uniQure's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for uniQure are expected to grow in the coming year, from ($3.82) to ($3.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of uniQure is -5.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of uniQure is -5.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatiouniQure has a P/B Ratio of 7.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about uniQure's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted13.18% of the float of uniQure has been sold short.Short Interest Ratio / Days to CoveruniQure has a short interest ratio ("days to cover") of 1.94, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in uniQure has recently decreased by 12.14%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YielduniQure does not currently pay a dividend.Dividend GrowthuniQure does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.20 News SentimentuniQure has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 13 news articles for uniQure this week, compared to 10 articles on an average week.Search Interest8 people have searched for QURE on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added uniQure to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, uniQure insiders have not sold or bought any company stock.Percentage Held by Insiders4.65% of the stock of uniQure is held by insiders.Percentage Held by Institutions78.83% of the stock of uniQure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about uniQure's insider trading history. Receive QURE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for uniQure and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. QURE Stock News HeadlinesWhy uniQure (QURE) Is Down 5.9% After Fresh Huntington’s Gene Therapy Data Update And What’s NextOctober 7 at 12:47 PM | finance.yahoo.comUNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 37.3% Share DropOctober 6, 2026 | businesswire.comNo. 1 stock to cash in on the death of iPhoneAnalyst Josh Baylin, who warned Congress about smartphones years before the iPhone launched, says the world's richest man may be building an iPhone rival he calls Starphone. Baylin points to FCC rulings, two trademarks filed the same day, multibillion-dollar spectrum deals, chip partnerships, and a string of posts from Elon Musk as evidence pointing to one conclusion. See the full research and the stock Baylin is watching now.October 10 at 1:00 AM | Stansberry Research (Ad)uniQure (NASDAQ:QURE) Shares Down 5.5% on Analyst DowngradeOctober 6, 2026 | americanbankingnews.comBarclays Downgrades uniQure to Equal Weight From OverweightOctober 5, 2026 | marketscreener.comMBarclays downgrades uniQure NV to equal-weight from overweightOctober 5, 2026 | msn.comuniQure (NASDAQ:QURE) Rating Lowered to "Equal Weight" at BarclaysOctober 5, 2026 | americanbankingnews.comBarclays Sticks to Their Buy Rating for uniQure (QURE)October 4, 2026 | theglobeandmail.comSee More Headlines QURE Stock Analysis - Frequently Asked Questions How have QURE shares performed this year? uniQure's stock was trading at $23.93 at the beginning of 2026. Since then, QURE stock has decreased by 5.6% and is now trading at $22.59. How were uniQure's earnings last quarter? uniQure N.V. (NASDAQ:QURE) posted its quarterly earnings results on Wednesday, July, 29th. The biotechnology company reported ($1.22) EPS for the quarter, missing analysts' consensus estimates of ($0.82) by $0.40. The biotechnology company had revenue of $5.84 million for the quarter, compared to the consensus estimate of $5.45 million. uniQure had a negative net margin of 1,350.73% and a negative trailing twelve-month return on equity of 111.96%. Read the conference call transcript. When did uniQure IPO? uniQure (QURE) raised $76 million in an IPO on Wednesday, February 5th 2014. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Who are uniQure's major shareholders? Top institutional shareholders of uniQure include Two Seas Capital LP (1.91%). Insiders that own company stock include Matthew C Kapusta, Christian Klemt, Walid Abi-Saab, Jeannette Potts, Kylie O'keefe, Pierre Caloz, Madhavan Balachandran, Jeremy P Springhorn, David D Meek, Leonard E Post, Rachelle Suzanne Jacques, Robert Gut and Jack Kaye. View institutional ownership trends. How do I buy shares of uniQure? Shares of QURE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of uniQure own? Based on aggregate information from My MarketBeat watchlists, some other companies that uniQure investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD), Advanced Micro Devices (AMD), Arista Networks (ANET) and ServiceNow (NOW). Company Calendar Last Earnings7/29/2026Today10/10/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 11 days, QURE's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:QURE CIK1590560 Webwww.uniqure.com Phone(120) 240-6000Fax31-20-566-9272Employees221Year Founded1868Price Target and Rating Average Price Target for uniQure$53.73 High Price Target$80.00 Low Price Target$28.00 Potential Upside/Downside+137.8%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)($4.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$198.97 million Net Margins-1,350.73% Pretax Margin-1,313.04% Return on Equity-111.96% Return on Assets-29.01% Debt Debt-to-Equity Ratio0.15 Current Ratio10.01 Quick Ratio10.01 Sales & Book Value Annual Sales$18.67 million Price / Sales83.92 Cash FlowN/A Price / Cash FlowN/A Book Value$3.19 per share Price / Book7.08Miscellaneous Outstanding Shares69,366,000Free Float66,140,000Market Cap$1.57 billion OptionableOptionable Beta1.06 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:QURE) was last updated on 10/10/2026 by MarketBeat.com Staff. From Our PartnersTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredInside a Former Merrill Lynch Advisor's Income PlaybookA former Merrill Lynch and Vanguard advisor spent 25 years watching one weekly options play generate consisten...Base Camp Trading | SponsoredNew Chip takes minutes, not daysGeorge Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...Eagle Publishing | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredInside the Options Play With a High Historical Win RateIan Cooper's newest strategy targets triple-digit returns in just 9 days. It doesn't work every time, but a 73...TradeWins | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding uniQure N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share uniQure With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
